

Date of preparation: 2022-08-02

Abbreviated name of the Issuer: MABION S.A.

Subject matter: Extension of cooperation with Novavax, Inc.

Legal basis: Article 17(1) of MAR - confidential information.

Content of the Report:

With reference to Current Report no. 52/2021 of 8 October 2021 on the conclusion of an agreement with Novavax, Inc. ("Novavax") regarding a commercial contract manufacturing agreement ("Manufacturing Agreement") and subsequent current reports on the expansion of the cooperation with Novavax, the Management Board of Mabion S.A. ("Company") hereby informs that on 2 August 2022, it signed a further extension of the scope of services provided under the Manufacturing Agreement with Novavax, in the form of Statement of Work #8 (SOW#8).

The scope of SOW#8 provides for the Company to carry out stability testing of the SARS CoV-2 rS active substance. The tests will be carried out in a GMP-compliant (Good Manufacturing Practice) environment, on the batches indicated by Novavax and manufactured at the Company's facility. It is a long-term order and it will be completed over a period of three years, for each batch tested.